Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Revenue | 3,974.24% | 2,017.02% | -6.67% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,974.24% | 2,017.02% | -6.67% | -- | -- |
| Cost of Revenue | 5,700.00% | 2,460.00% | -100.00% | -- | -- |
| Gross Profit | 3,468.63% | 1,809.38% | 40.00% | -- | -- |
| SG&A Expenses | -75.61% | -112.21% | -94.01% | 0.65% | 167.41% |
| Depreciation & Amortization | 74.89% | -192.47% | 13.52% | -19.66% | -40.51% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -74.40% | -118.05% | -93.63% | 0.26% | 163.92% |
| Operating Income | 76.53% | 118.54% | 93.65% | -0.18% | -163.78% |
| Income Before Tax | 96.15% | -100.07% | -171.76% | -503.29% | -889.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.15% | -100.09% | -171.76% | -503.29% | -889.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 105.20% | -262.05% | -236.57% | -219.39% | -218.62% |
| Net Income | 96.19% | -96.53% | -165.81% | -477.53% | -823.02% |
| EBIT | 76.53% | 118.54% | 93.65% | -0.18% | -163.78% |
| EBITDA | 73.82% | 120.34% | 102.97% | 16.33% | -135.70% |
| EPS Basic | 97.04% | -17.51% | -39.03% | -143.96% | -276.14% |
| Normalized Basic EPS | 95.45% | 29.22% | 6.44% | -88.89% | -296.72% |
| EPS Diluted | 97.04% | -17.51% | -39.03% | -143.96% | -276.14% |
| Normalized Diluted EPS | 95.45% | 29.22% | 6.44% | -88.89% | -296.72% |
| Average Basic Shares Outstanding | 45.71% | 79.04% | 120.88% | 150.68% | 134.95% |
| Average Diluted Shares Outstanding | 45.71% | 79.04% | 120.88% | 150.68% | 134.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
